The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States

Because chronic liver disease may develop many years after acute hepatitis C virus (HCV) infection, the past incidence of acute infections is a major determinant of the future burden of HCV‐associated complications. We estimated past incidence of acute HCV infection using national seroprevalence data and relative age‐specific incidence data from a sentinel counties surveillance system. Projections of the future prevalence of HCV‐infected patients were derived from models that included an 85% drop in HCV infection incidence as observed for reported cases in the early 1990s. The models showed a large increase in the incidence of HCV infections from the late 1960s to the early 1980s. The degree of increase was dependent on the assumed rate of antibody loss; a model with 2.5% annual antibody loss showed annual incidence increasing from 45,000 infections (95% confidence interval [95% CI]: 0‐110,000) in the early 1960s to 380,000 infections (95% CI: 250,000 to 500,000) in the 1980s. Projections showed that although the prevalence of HCV infection may be declining currently because of the decline in incidence in the 1990s, the number of persons infected for ≥20 years could increase substantially before peaking in 2015. If the incidence of new HCV infections does not increase in the future, persons born between 1940 and 1965 will be at highest lifetime risk of acquiring the infection.

[1]  M A Gerber,et al.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. , 1992, The New England journal of medicine.

[2]  R. Koretz,et al.  Non‐A, non‐B posttransfusion hepatitis: Comparing C and non‐C hepatitis , 1993, Hepatology.

[3]  F. Iber,et al.  Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis , 1992 .

[4]  D. Kleinbaum,et al.  Applied regression analysis and other multivariable methods, 3rd ed. , 1998 .

[5]  E. L. Wallace,et al.  Methods must match the mission , 1994, Transfusion.

[6]  G. Woody,et al.  Causes of death in injection-drug users. , 1993, The New England journal of medicine.

[7]  D. Gretch Diagnostic tests for hepatitis C , 1997, Hepatology.

[8]  K. Ishak,et al.  Long‐term clinical and histopathological follow‐up of chronic posttransfusion hepatitis , 1991, Hepatology.

[9]  D. Fleming,et al.  Mortality among injection drug users identified as "out of treatment". , 1995, American journal of public health.

[10]  M. Alter,et al.  The effect of underreporting on the apparent incidence and epidemiology of acute viral hepatitis. , 1987, American journal of epidemiology.

[11]  G. Nemo,et al.  HEPATITIS C VIRUS INFECTION IN POST-TRANSFUSION HEPATITIS - AN ANALYSIS WITH FIRST - AND SECOND - GENERATION ASSAYS , 1991 .

[12]  A. Ades,et al.  Modeling age- and time-specific incidence from seroprevalence:toxoplasmosis. , 1993, American journal of epidemiology.

[13]  C. C. Spicer,et al.  Catalytic Models in Epidemiology. , 1959 .

[14]  L. Seeff The natural history of hepatitis C—A quandary , 1998, Hepatology.

[15]  A. Alberti,et al.  Antibody to hepatitis C virus in post-transfusion hepatitis. , 1991, Annals of internal medicine.

[16]  H. Margolis,et al.  Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. , 1990, JAMA.

[17]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[18]  Edoardo Cervoni,et al.  Hepatitis C , 1998, The Lancet.

[19]  M. Alter,et al.  Epidemiology of Hepatitis C , 2018, Clinical liver disease.

[20]  T. Tsuji,et al.  Natural course of chronic hepatitis C. , 1993, The American journal of gastroenterology.

[21]  M. Houghton,et al.  Hepatitis C virus antibodies in acute icteric and chronic non-A, non-B hepatitis. , 1991, Gastroenterology.

[22]  J. Hoofnagle,et al.  Hepatitis C: The clinical spectrum of disease , 1997, Hepatology.

[23]  J. M. Calvo Romero,et al.  Gastric adenocarcinoma and kidney transplantation , 1998 .

[24]  M. Roggendorf,et al.  Long-term persistence of hepatitis C virus antibodies in a single source outbreak. , 1991, Journal of hepatology.

[25]  E. Vamvakas,et al.  Long‐term survival after blood transfusion , 1994, Transfusion.